



The CCS is committed to preserving the scientific integrity of its Guidelines, Clinical Practice Updates and Position Statements through transparency and management of disclosures (industry, academic, financial benefits and other conflicts). Invited and approved panel members must disclose all relationships regardless of relevance to the topic. When a potential conflict exists, the affected member must recuse during the formal consensus voting process. For more information on the CCS Guideline Development process, please visit [www.ccs.ca](http://www.ccs.ca). Updated March 8, 2023.

Members		Consulting Fees / Honoraria	Clinical Trials	Other Financial Benefits	Relevance to Statement
<b>Panel members</b>					
First name	Last name				
Jean-Luc	Bigras	None	None	None	
Beth	Cummings	Pfizer	Harris	None	Advisory board to Pfizer related to growth hormone, Advisory Board Insulet (insulin pumps)
Kevin	Harris	None	Janssen	None	None
Robert	Hegele	Amgen, Akcea/Ionis, Arrowhead, Boston Heart, HLS Therapeutics, Novartis, Pfizer, Regeneron, Sanofi, UltraGenyx	The Medicines Company, Regeneron, Novartis, Amgen, Arrowhead	None	These companies either make and market lipid-lowering agents or are developing new investigational products for treating severe dyslipidemia.
Melanie	Henderson	None	Sanofi, Levo Therapeutics	None	The study sponsored by Levo Therapeutics was not related to the topic of the guideline. I was sub-investigator on the study sponsored by Sanofi. This study was about homozygous familial hypercholesterolemia. This study was closed in our center in March 2019 and no subject was enrolled in our center.
Michael	Khoury	Ultragenyx	Site PI for Esperion Therapeutic	None	Esperion Therapeutics study is concerning a treatment for heterozygous familial hypercholesterolemia. The specific treatment is not discussed in the CPU. Re: Ultragenyx - no relevance
Brian	McCrinkle	Amryt Pharma, Chiesi, Esperion, Ultragenyx	None	None	None
Katherine	Morrison	NovoNordisk, Novartis (Data Safety Monitoring Committee)	None	None	Advisory Board for Obesity; DSMB for a lipid lowering agent
Julie	St. Pierre	Novo Nordisk, Bausch & Health	Amgen	None	Advisory board on obesity, no influence. Trial Amgen over since 2020
Peter	Wong	None	None	None	